CO6400140A2 - Derivados de benzotiazol como agentes anticancer - Google Patents

Derivados de benzotiazol como agentes anticancer

Info

Publication number
CO6400140A2
CO6400140A2 CO11082152A CO11082152A CO6400140A2 CO 6400140 A2 CO6400140 A2 CO 6400140A2 CO 11082152 A CO11082152 A CO 11082152A CO 11082152 A CO11082152 A CO 11082152A CO 6400140 A2 CO6400140 A2 CO 6400140A2
Authority
CO
Colombia
Prior art keywords
benzotiazol
derivatives
anticancer agents
cancer
inhibitory activity
Prior art date
Application number
CO11082152A
Other languages
English (en)
Inventor
Masanori Okaniwa
Terufumi Tagaki
Hirose Masaaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400140(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6400140A2 publication Critical patent/CO6400140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

Un compuesto representado por la fórmulael cual posee una fuerte actividad inhibidora de Raf (particularmente, actividad inhibitoria de B-Raf) y puede proporcionar un agente clínicamente útil para la profilaxis o tratamiento de cáncer, un inhibidor del crecimiento del cáncer y un agente supresor de metástasis de cáncer.
CO11082152A 2008-12-02 2011-06-30 Derivados de benzotiazol como agentes anticancer CO6400140A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25

Publications (1)

Publication Number Publication Date
CO6400140A2 true CO6400140A2 (es) 2012-03-15

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11082152A CO6400140A2 (es) 2008-12-02 2011-06-30 Derivados de benzotiazol como agentes anticancer

Country Status (41)

Country Link
US (2) US8143258B2 (es)
EP (1) EP2358689B9 (es)
JP (1) JP5640014B2 (es)
KR (1) KR101639092B1 (es)
CN (1) CN102300854B (es)
AR (1) AR074435A1 (es)
AU (1) AU2009323274B2 (es)
BR (1) BRPI0922109A2 (es)
CA (1) CA2745144C (es)
CL (1) CL2011001299A1 (es)
CO (1) CO6400140A2 (es)
CR (1) CR20110366A (es)
CY (1) CY1117178T1 (es)
DK (1) DK2358689T5 (es)
DO (1) DOP2011000165A (es)
EA (1) EA019447B1 (es)
EC (1) ECSP11011165A (es)
ES (1) ES2557304T3 (es)
GE (1) GEP20146003B (es)
HK (1) HK1161236A1 (es)
HR (1) HRP20151370T1 (es)
HU (1) HUE026491T4 (es)
IL (1) IL213184A0 (es)
JO (1) JO3101B1 (es)
MA (1) MA32911B1 (es)
ME (1) ME02331B (es)
MX (1) MX2011005836A (es)
MY (1) MY150989A (es)
NZ (1) NZ593759A (es)
PE (1) PE20110588A1 (es)
PL (1) PL2358689T3 (es)
PT (1) PT2358689E (es)
RS (1) RS54370B9 (es)
SG (1) SG171426A1 (es)
SI (1) SI2358689T1 (es)
SM (1) SMT201500316B (es)
TN (1) TN2011000280A1 (es)
TW (1) TWI436987B (es)
UY (1) UY32281A (es)
WO (1) WO2010064722A1 (es)
ZA (1) ZA201104659B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162445B1 (en) * 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
WO2009025358A1 (ja) * 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
US20150126533A1 (en) * 2012-03-30 2015-05-07 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
WO2014031732A2 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
BR112015032539B1 (pt) 2013-06-28 2022-07-12 Beigene, Ltd Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos
EP3013797B1 (en) 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
WO2016008048A1 (en) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
EP3236966B1 (en) * 2014-12-23 2020-08-12 DOT Therapeutics-1, Inc. Combination of raf inhibitors and taxanes
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
WO2020097398A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) * 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP2001517699A (ja) 1997-09-26 2001-10-09 アスタ メディカ アクチエンゲゼルシャフト セリン／トレオニンプロテインキナーゼ作用の変性のためのアザベンズイミダゾールを基礎とする化合物
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
BRPI0007487B8 (pt) * 1999-01-13 2021-05-25 Bayer Healthcare Llc difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1183114C (zh) * 1999-01-22 2005-01-05 麒麟麦酒株式会社 喹啉衍生物及喹唑啉衍生物
BR0012046A (pt) 1999-07-01 2002-05-14 Ajinomoto Kk Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
SK287401B6 (sk) 1999-11-05 2010-09-07 Astrazeneca Ab Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
NZ520640A (en) 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2003525936A (ja) 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
YU96502A (sh) 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
DK1318992T3 (da) 2000-09-21 2005-11-21 Smithkline Beecham Plc Imidazolderivater som Raf-kinaseinhibitorer
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1423383B1 (en) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
US20040192689A1 (en) 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1487824B1 (en) 2002-03-01 2007-06-20 SmithKline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
PT1682126E (pt) 2003-10-16 2009-10-02 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da quinase raf
CA2565200C (en) 2004-05-07 2013-12-24 Exelixis, Inc. Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20060079098A (ko) 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
JP2008528585A (ja) * 2005-01-26 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
SI2010528T1 (en) 2006-04-19 2018-02-28 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
BRPI0714665A2 (pt) 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
WO2008125633A2 (en) 2007-04-13 2008-10-23 Rikshospitalet - Radiumhospitalet Hf Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKERS FOR MELANOMES
WO2008147782A1 (en) 2007-05-23 2008-12-04 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009028629A1 (ja) 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
ZA201104659B (en) 2012-08-29
SI2358689T1 (sl) 2016-01-29
PT2358689E (pt) 2015-12-30
WO2010064722A1 (en) 2010-06-10
HUE026491T4 (en) 2017-07-28
TWI436987B (zh) 2014-05-11
EP2358689B1 (en) 2015-09-30
HUE026491T2 (en) 2016-06-28
JP2012510467A (ja) 2012-05-10
CL2011001299A1 (es) 2012-01-13
MA32911B1 (fr) 2011-12-01
HK1161236A1 (zh) 2012-08-24
SG171426A1 (en) 2011-07-28
SMT201500316B (it) 2016-01-08
IL213184A0 (en) 2011-07-31
EP2358689B9 (en) 2016-08-03
HRP20151370T1 (hr) 2016-01-15
UY32281A (es) 2010-06-30
DK2358689T5 (en) 2016-10-10
CR20110366A (es) 2011-08-29
ES2557304T3 (es) 2016-01-25
PE20110588A1 (es) 2011-09-08
CY1117178T1 (el) 2017-04-05
DK2358689T3 (en) 2015-12-14
MY150989A (en) 2014-03-31
ECSP11011165A (es) 2011-07-29
BRPI0922109A2 (pt) 2020-09-01
AR074435A1 (es) 2011-01-19
NZ593759A (en) 2012-07-27
RS54370B9 (sr) 2020-01-31
KR20110091039A (ko) 2011-08-10
JO3101B1 (ar) 2017-09-20
RS54370B1 (en) 2016-04-28
JP5640014B2 (ja) 2014-12-10
AU2009323274A1 (en) 2011-07-07
CN102300854B (zh) 2015-01-07
US20120214855A1 (en) 2012-08-23
TW201024272A (en) 2010-07-01
KR101639092B1 (ko) 2016-07-12
EA201170735A1 (ru) 2011-12-30
AU2009323274B2 (en) 2015-09-17
DOP2011000165A (es) 2011-06-30
US8497274B2 (en) 2013-07-30
ME02331B (me) 2016-04-28
EA019447B1 (ru) 2014-03-31
PL2358689T3 (pl) 2016-03-31
US8143258B2 (en) 2012-03-27
US20100216810A1 (en) 2010-08-26
EP2358689A1 (en) 2011-08-24
GEP20146003B (en) 2014-01-10
CA2745144A1 (en) 2010-06-10
CA2745144C (en) 2017-10-03
TN2011000280A1 (en) 2012-12-17
CN102300854A (zh) 2011-12-28
MX2011005836A (es) 2011-06-17

Similar Documents

Publication Publication Date Title
CO6400140A2 (es) Derivados de benzotiazol como agentes anticancer
CR20120448A (es) Compuesto heterocíclico
HN2011000629A (es) Derivados de picolinamida como inhibidores de cinasa
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
ECSP13012985A (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
ECSP10010526A (es) Compuesto heterociclico
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
SG190819A1 (en) Nampt and rock inhibitors
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
EA201171367A1 (ru) Винилиндазолильные соединения
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CR20120296A (es) Nuevos compuestos de espiropiperidina
PA8850801A1 (es) Compuestos útiles para inhibir chk1
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
ATE510822T1 (de) Kaliumkanalinhibitoren
MX348311B (es) Inhibidores nampt.
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MD3615544T2 (ro) Compuși antitumorali
UA104002C2 (ru) МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa
MX2015012043A (es) Agonistas muscarinicos.
MA33932B1 (fr) Dérivés de 2-aldoximino-5-fluoropyrimidine
ECSP077208A (es) Inhibidores de los canales de potasio

Legal Events

Date Code Title Description
FG Application granted